Clinical Trial Update: Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022) [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating adjuvant targeted therapy guided by ctDNA-MRD in EGFR-mutant non-small cell lung cancer after surgery.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer
• Non-small Cell Lung Cancer

Snippet

Sponsor: Fudan University | Conditions: Lung Cancer, EGFR Gene Mutation | Phase 3 | Status: NOT_YET_RECRUITING